Related Experiment Video
Updated: Jul 19, 2026
09:11
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
Current treatment in cardiac amyloidosis
Ivana Kholová1, Josef Kautzner
1Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland. Ivana.Kholova@uku.fi
Current Treatment Options in Cardiovascular Medicine
|November 3, 2006
Summary
Cardiac amyloidosis, a common heart condition, presents variedly and requires accurate diagnosis via tissue biopsy. Treatment strategies are tailored to amyloid type and disease stage, with emerging therapies showing promise.
Area of Science:
- Cardiology
- Hematology
- Pathology
Background:
- Cardiac amyloidosis is a frequent manifestation of systemic amyloidosis.
- Amyloid fibril infiltration of the heart occurs in primary, age-related, transthyretin familial, and secondary amyloidosis.
- Clinical presentations include restrictive cardiomyopathy, heart failure, arrhythmias, and orthostatic hypotension.
Purpose of the Study:
- To summarize the common cardiac involvements in amyloidosis.
- To outline diagnostic methods and therapeutic strategies for cardiac amyloidosis.
- To highlight emerging treatment options for this condition.
Main Methods:
- Diagnosis relies on tissue sample confirmation, with Congo red staining and polarized light microscopy as the gold standard.
- Protein fibril typing via immunohistochemistry or biochemistry is crucial for prognosis and treatment planning.
- Review of current and investigational therapeutic approaches for different amyloidosis types.
Main Results:
- Restrictive cardiomyopathy with right-sided heart failure is the most common presentation.
- Supportive care, including diuretics, is key for cardiac failure management.
- Specific treatments vary by amyloid type, with chemotherapy (melphalan, prednisone) for primary amyloidosis and transplantation for transthyretin amyloidosis.
Conclusions:
- Accurate diagnosis and typing of amyloidosis are essential for effective management.
- Treatment is multi-faceted, combining amyloid-specific therapies with cardiac supportive care.
- Novel therapies, including stem cell transplantation and targeted treatments, offer future therapeutic avenues.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...